GENELUX Corp (GNLX) stock
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.00+0.08 (+4.17%)
Close on Nov 17, 2026Market cap $90.49MP/E –Yield –
Genelux r&d expenses
Research and development expenses are spending on new products and technology.
Genelux's R&D Expenses for the twelve months ending Jun 30, 2026 was $22.68M, up 13.3% year over year. For fiscal 2025 it was $19.85M, up 4.5% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.85M | +4.5% |
| FY2024 | Dec 31, 2024 | $19.00M | +48.8% |
| FY2023 | Dec 31, 2023 | $12.77M | +40.6% |
| FY2022 | Dec 31, 2022 | $9.08M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.51M | +36.8% |
| Q1 FY2026 | Mar 31, 2026 | $5.78M | +23.0% |
| Q4 FY2025 | Dec 31, 2025 | $5.65M | -13.3% |
| Q3 FY2025 | Sep 30, 2025 | $4.74M | +17.0% |
| Q2 FY2025 | Jun 30, 2025 | $4.76M | +7.7% |
| Q1 FY2025 | Mar 31, 2025 | $4.70M | +17.2% |
| Q4 FY2024 | Dec 31, 2024 | $6.52M | +56.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.05M | +43.7% |
| Q2 FY2024 | Jun 30, 2024 | $4.42M | +50.1% |
| Q1 FY2024 | Mar 31, 2024 | $4.01M | +40.9% |
| Q4 FY2023 | Dec 31, 2023 | $4.16M | +68.6% |
| Q3 FY2023 | Sep 30, 2023 | $2.82M | +16.8% |
| Q2 FY2023 | Jun 30, 2023 | $2.94M | +61.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.85M | +20.1% |
| Q4 FY2022 | Dec 31, 2022 | $2.47M | – |
| Q3 FY2022 | Sep 30, 2022 | $2.41M | – |
| Q2 FY2022 | Jun 30, 2022 | $1.83M | – |
| Q1 FY2022 | Mar 31, 2022 | $2.37M | – |
See a number that looks wrong?